Fusion Income Before Tax vs Total Other Income Expense Net Analysis
| FUSN Stock | USD 21.52 0.03 0.14% |
Fusion PharmaceuticalsI financial indicator trend analysis is much more than just examining Fusion PharmaceuticalsInc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fusion PharmaceuticalsInc is a good investment. Please check the relationship between Fusion PharmaceuticalsI Income Before Tax and its Total Other Income Expense Net accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Income Before Tax vs Total Other Income Expense Net
Income Before Tax vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fusion PharmaceuticalsInc Income Before Tax account and Total Other Income Expense Net. At this time, the significance of the direction appears to have very week relationship.
The correlation between Fusion PharmaceuticalsI's Income Before Tax and Total Other Income Expense Net is 0.21. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Fusion PharmaceuticalsInc, assuming nothing else is changed. The correlation between historical values of Fusion PharmaceuticalsI's Income Before Tax and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Fusion PharmaceuticalsInc are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Income Before Tax i.e., Fusion PharmaceuticalsI's Income Before Tax and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.21 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Fusion PharmaceuticalsI income statement and is an important metric when analyzing Fusion PharmaceuticalsInc profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Total Other Income Expense Net
Most indicators from Fusion PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fusion PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, Fusion PharmaceuticalsI's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 23rd of May 2024, Enterprise Value is likely to grow to about 649.9 M, though Tax Provision is likely to grow to (806.5 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 634K | 909K | 1.2M | 1.3M | Total Operating Expenses | 83.5M | 89.5M | 100.0M | 54.3M |
Fusion PharmaceuticalsI fundamental ratios Correlations
Click cells to compare fundamentals
Fusion PharmaceuticalsI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fusion PharmaceuticalsI fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 155.7M | 22.0M | 42.6M | 43.7M | 65.6M | 57.7M | |
| Total Assets | 69.4M | 310.7M | 252.3M | 219.1M | 285.8M | 214.3M | |
| Other Current Liab | 3.4M | 7.5M | 7.6M | 10.0M | 9.9M | 7.3M | |
| Total Current Liabilities | 4.3M | 11.9M | 12.5M | 15.1M | 16.2M | 11.3M | |
| Total Stockholder Equity | (33.5M) | 294.5M | 231.5M | 162.2M | 222.5M | 157.5M | |
| Other Liab | 321K | 4.3M | 2.8M | 3.0M | 3.4M | 2.3M | |
| Net Tangible Assets | (33.5M) | 294.5M | 231.5M | 162.2M | 186.6M | 140.1M | |
| Property Plant And Equipment Net | 1.3M | 2.0M | 9.5M | 10.3M | 23.9M | 25.1M | |
| Net Debt | (59.6M) | (90.5M) | (46.2M) | (3.6M) | (11.6M) | (12.2M) | |
| Retained Earnings | (34.8M) | (113.2M) | (194.3M) | (281.9M) | (376.8M) | (357.9M) | |
| Accounts Payable | 830K | 3.4M | 2.2M | 2.7M | 1.9M | 2.1M | |
| Cash | 65.3M | 90.5M | 52.9M | 43.9M | 61.9M | 62.9M | |
| Non Current Assets Total | 2.8M | 82.5M | 40.5M | 40.1M | 42.4M | 38.4M | |
| Non Currrent Assets Other | 1.5M | 2.8M | 9.4M | 9.2M | 849K | 806.6K | |
| Other Assets | 1.6M | 80.5M | 11.1M | 14.0M | 16.1M | 23.6M | |
| Cash And Short Term Investments | 65.3M | 222.4M | 200.8M | 186.6M | 234.1M | 172.0M | |
| Net Receivables | 428K | 794K | 357K | 1.7M | 4.2M | 4.4M | |
| Liabilities And Stockholders Equity | 69.4M | 310.7M | 252.3M | 219.1M | 285.8M | 214.3M | |
| Non Current Liabilities Total | 98.6M | 4.3M | 8.3M | 41.8M | 47.1M | 33.0M | |
| Capital Surpluse | 1.3M | 407.7M | 425.8M | 444.6M | 511.2M | 281.6M | |
| Inventory | 503K | 4.2M | 10.4M | (9.9M) | (8.9M) | (8.4M) | |
| Other Current Assets | 278K | 727K | 233K | 509K | 5.1M | 5.4M | |
| Other Stockholder Equity | (70.3M) | 407.7M | 425.8M | 444.6M | 599.0M | 331.4M | |
| Total Liab | 102.9M | 16.2M | 20.8M | 56.8M | 63.4M | 41.2M | |
| Net Invested Capital | (33.5M) | 294.5M | 231.5M | 196.5M | 257.3M | 170.2M | |
| Property Plant And Equipment Gross | 1.3M | 2.0M | 9.5M | 12.3M | 26.4M | 27.7M | |
| Total Current Assets | 66.6M | 228.2M | 211.8M | 179.0M | 243.4M | 175.8M | |
| Accumulated Other Comprehensive Income | (428K) | 44K | (115K) | (469K) | 237K | 248.9K | |
| Net Working Capital | 62.3M | 216.3M | 199.3M | 163.9M | 227.2M | 164.6M | |
| Property Plant Equipment | 1.3M | 2.0M | 3.0M | 4.6M | 5.3M | 5.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.